NATCO Pharma Ltd Receives Approval for Semaglutide Injection in India

NATCO Pharma Limited has received approval from the Central Drugs Standard Control Organisation (CDSCO) to manufacture and market generic Semaglutide Injection in India. The product is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise. NATCO is a R&D oriented, and a science driven leading Oncology player in the targeted therapies of the domestic market, focusing on limited competition molecule in the US. The company has 9 manufacturing sites and 2 R&D facilities in India, approved by several leading regulatory authorities like U.S. FDA, Brazil ANVISA, Health Canada, WHO and others, catering to 50+ global markets.